Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calciu... ( CONSHOHOCKEN PA and VANCOUVER BC June...)

HOME >> MEDICINE >> NEWS

Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels

Date:6/11/2009

CONSHOHOCKEN, PA and VANCOUVER, BC, June 11 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that it has received notification that Merck & Co., Inc. will terminate the research collaboration and license agreement for novel compounds targeting N-type calcium channels for the treatment of pain and other disorders, which the companies entered into in March of 2006.

"Over the past three years we have had an excellent and extremely productive collaboration with our colleagues at Merck. The molecules generated in our collaboration, while effective in disease models, did not demonstrate the profile needed to enter the next phase of testing, including human clinical trials. We remain confident in our goal to generate a new class of medicines from our platform," said Dr. Christopher Gallen, President & CEO of Neuromed. "Neuromed is a leader in ion channel research and we remain committed to further research and development in this field."

N-type calcium channel blockers represent a potentially novel class of analgesics that are selective for calcium channels involved in pain signal transmission. Calcium channels control the entry of calcium into the neuron. When a pain signal is transmitted, the channel opens and the calcium concentration increases, triggering the release of neurotransmitters from synaptic vesicles, thereby sending the pain signal to the brain where it is perceived as pain.

About Neuromed

Neuromed is a privately held biopharmaceutical company focusing on the development of new and improved pain medicines. Its lead drug candidate is EXALGO(TM) (hydromorphone HCl) Extended-Release Tablets. In addition to its N-type program, Neuromed is also developing oral drug candidates to block T-type calcium channels, a new and important target directly involved in pain, epilepsy and hypertension. For more information visit our website at www.neurom
'/>"/>

SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
7. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
8. $10 Million Gift to Transform Neuromedicine at URMC
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West

Post Your Comments:

(Date:12/1/2009)...Could identify those who would benefit from liver ...UESDAY, Dec. 1 (HealthDay News) -- A CT scan of li...er may help predict overall survival after chemoth... (Avastin) to cytotoxic chemotherapy has been show...colorectal cancer and to produce better results in...

(Date:12/1/2009)... , MIAMI, FL (December 1, 2009)The Clinical Resea...ler School of Medicine, has been honored for its s... the LEED designation, established by the U.S. Gre...ding Certification Institute (GBCI). LEED is the n...ction and operation of green buildings., "Having ...

(Date:12/1/2009)..., , SMITHFIELD, R.I., Dec...ective equipment, bad assumptions are hazardous an...5 years of government regulation, a handful of per...ing both the effectiveness of occupational Hearin...ing. ,, A new free, white paper from Howard Le...

(Date:12/1/2009)..., , WASHINGTON, Dec. 1 /PRNewswire-USNewswi... Agency for International Development: ,, Chair...e Committee. ,, I am honored to be nominated by...United States Agency for International Development...e Agency. ,, Secretary of State Clinton has ex...

(Date:12/1/2009)... Barcelona, 30 November 2009. Performing surgica...e a chimera and has become a reality. This is demo...g NOTES (Natural Orifice Transluminal Endoscopy Su...s surgical access using the body,s natural orifice...t: lack of scars, shorter hospital stay and faster...

[0] CT Scan May Predict Colon Cancer Survival [0] UM Clinical Research Building awarded prestigious LEED Building Certification [0] New White Paper Details Six Common Bad Assumptions About Hearing Protection [0] Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 [0] Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus

... Ethnic rhinoplasty will be discusse...American Society for Aesthetic Plastic Surgery (AS...nvention Center May 2-7, 2009. , ...both their individuality and ethnic identity. But...

... Non-surgical facial rejuvenation te...he Annual Meeting of the American Society for Aest...andalay Bay Hotel & Convention Center May 2-7,... can erase wrinkles, tighten the skin, and improve...

... Nashville hair transplant center, P...sed on expanding their serviceable region. PAI Nas...phis, Knoxville, Clarksville, Chattanooga, Birming...spread throughout Tennessee, Kentucky, and Alabama...

... As citizens search to protect thems...otections may actually be right under our nose. Br...ing this crisis , New Por...itizens are mobilizing to protect themselves by we...

...ed $750,000 by Avon Foundation for Breast Cancer A...nne Mandelblatt, MD, MPH, and Harriet Weiner have ...ion to walk to raise funds and awareness of breast... Lombardi. , , The team has been training since ...

...H1N1 strain lacks "virulent characteristics" of de...ay 2 (HealthDay News) -- The scope of the swine fl... thought, test results released Friday in Mexico s... people have died. , Mexico had reported about 2,5...

Ethnic Rhinoplasty: The "Classic" Nose Job is Not One Size Fits All Saving Face...No Need For A Knife! Hair Transplant Office Expands Serviceable Area Cleanose Personal Air Filters Offer Added Protection From Inhaled Viruses/ Swine Flu/ H1N1 and Other Inhaled Dangers Georgetown's Lombardi Comprehensive Cancer Center and the Capital Breast Care Center Pound the Pavement to Save Lives Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought

(Date:12/1/2009)... Dec. 1 CCS Medical, Inc. a leadin... today announced that it has received approval fro...of Delaware (the "Court") for its bidding procedur...ale of substantially all of its assets. ,, Purs...t approved bidding procedures for the sale of subs...

(Date:12/1/2009)... 1 CEL-SCI Corporation (...nd a developer of vaccines and therapeutics for th... announced today that it has retained the services...n (CRO) to run CEL-SCI,s upcoming Phase III clinic...with the Company,s lead product candidate, Multiki...

(Date:12/1/2009)... Dec. 1 MedQuist Inc. ...-enabled clinical documentation services, today an...dial Design, Inc. has been integrated with SpeechQ...cognition system. The solution is being demonstrat...SNA) convention November 29 through December 2. ...

Breaking Medicine Technology:CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3 MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 1 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 1 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 3 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 4 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 1 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 2 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 3 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 4

[0] CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures [0] CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine [0] MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology

...-Company to Host Conference Call at 9:00 a.m. EDT-... Corp. (Nasdaq: MEMY ) today announced top-line d...d, placebo-controlled Phase 2a study,of MEM 1003, ...zheimer,s,disease. The trial enrolled 183 subjects... 40 centers in the United States and included mono...

...ORLANDO, Fla., Oct. 13 Acutely ill, hospitalized,...rovement in symptoms,after taking INVEGA(TM) (pali...SEROQUEL(R)(a) (quetiapine) and placebo. Symptom i...ve days into therapy and continued,through the end...inary data,presented today at the 20th Annual U.S....

Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...

Medicine Products:

Antifungal Serum Level, Itraconazole Antidiuretic Hormone, Plasma Antidepressant Panel Anticochlear

Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calciu...( CONSHOHOCKEN PA and VANCOUVER BC June...),Health